Skip to Content

Posts tagged with "Drug Industry History"

  • Business and Markets

    Pharma’s Return on Investment: Yikes

    There’s a recent article in Nature Reviews Drug Discovery that has some alarming figures in it. This is yet another look at the industry from McKinsey, and we’ll get to their McKinseyish solutions in a moment. But first, some numbers: They calculate that the return on investment (ROI) from small-molecule drug research was nearly 12% Read More
  • Academia (vs. Industry)

    Where Drugs Come From, and How. Once More, With A Roll of the Eyes

    I linked yesterday to a post by Megan McArdle about health care reform. And while I realize that everyone got into a shouting match in the comments to my own post on the subject – and people sure did in the comments to hers; it’s endemic – I wanted to quote a section from her… Read More
  • Alzheimer's Disease

    Amyloid in Trouble

    Here’s an interesting look at the current state of the Alzheimer’s field from Bloomberg. The current big hope is Wyeth (and Elan)’s bapineuzumab, which I last wrote about here. That was after the companies reported what had to be considered less-than-hoped-for efficacy in the clinic. The current trial is the one sorted out by APOE… Read More
  • Business and Markets

    Drug Approvals, Natural And Unnatural

    I seem to have been putting a lot of graphics up this week, so here’s another one. This is borrowed from a recent Science paper on the future of natural-products based drug discovery. It’s interesting both from that viewpoint, and because of the general approval numbers: And there you have it. Outside of anomalies like… Read More
  • Drug Assays

    Why Does Screening Work At All? (Free Business Proposal Included!)

    I’ve been meaning to get around to a very interesting paper from the Shoichet group that came out a month or so ago in Nature Chemical Biology. Today’s the day! It examines the content of screening libraries and compares them to what natural products generally look like, and they turn up some surprising things along… Read More
  • Business and Markets

    How Much Does the Drug Industry Spend on Marketing?

    Anyone who defends the pharmaceutical industry has to be ready to hear, over and over and over, about how much it spends on sales and marketing versus R&D. This is thought to be a telling point about where the priorities really are. I’ve addressed this one several times, and my best response is to point… Read More
  • Drug Industry History

    Jargon Will Save Us All

    Moore’s Law: number of semiconductors on a chip doubling every 18 months or so, etc. Everyone’s heard of it. But can we agree that anyone who uses it as a metaphor or perscription for drug research doesn’t know what they’re talking about? I first came across the comparison back during the genomics frenzy. One company… Read More
  • Business and Markets

    GSK’s Getting Better. Just Ask the CEO.

    There are some interesting statements from GlaxoSmithKline CEO Andrew Witty here at Reuters. He admits that morale was completely in the scupper around the place a few months ago, which certainly seems to be true, but says that they’re turning things around. To that point, remember all that stuff a few years ago about how… Read More
  • Drug Development

    The View From Pfizer’s Corner Offices

    There’s a good article from Lee Howard up at The Day (the New London/Groton newspaper) on the changes going on at Pfizer. It’s the story according to management, though, which is worth having for its compare-and-contrast uses: Despite the looming uncertainty, according to company spokesmen, the new research structure has added energy an… Read More
  • Business and Markets

    CafePharma Will Now Approach The Bench

    Here’s an interesting situation for you: according to IguanaBio, a shareholder lawsuit over the failed Vytorin ENHANCE clinical trial (that’s caused Schering-Plough and Merck so much grief) is going to use posts on CafePharma as evidence. That will be worth watching. CafePharma’s message boards have been described (accurately, I&# Read More